Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 4,170 shares at $13.43 ($56K) on 2026-04-06, disclosed to the SEC on 2026-04-06.
Scheduled sale ($56k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-03-02 | $63K | — | Filing → |